Neomycin And Polymyxin B Sulfates And Hydrocortisone Otic Suspension
Pricing Report NDC 64980-448-01

Current NADAC: $3.78944 per ML · Effective Aug 19, 2026
Table of Contents
  1. Current Pricing Information
  2. Pricing History

Current Package Pricing Information

The current wholesale acquisition cost for Neomycin And Polymyxin B Sulfates And Hydrocortisone Otic Suspension (NDC 64980-448-01) is $3.78944 per ML. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Aug 19, 2026.

As a a human prescription drug provided by Rising Pharma Holdings, Inc., this medication is distributed in a 1 BOTTLE in 1 CARTON / 10 mL in 1 BOTTLE configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.

NADAC Pricing Summary

NADAC pricing snapshot for this package NDC

Acquisition Cost
$3.78944
Per ML

Pricing Unit
Per ML Pricing Unit
Indicates the billing unit (ML, GM or EA).
Effective Date
Aug 19, 2026
Data Status
As of Sep 09, 2026
Pharmacy Source Pharmacy Type Indicator
Data collected from Chain/Independent pharmacy surveys.
C/I - Chain or Independent Pharmacy
Rate Classification Classification for Rate Setting
Indicates if the NDC is Brand (B) or Generic (G).
G - Generic
Package NDC
64980-448-01
Description
1 BOTTLE in 1 CARTON / 10 mL in 1 BOTTLE
Pricing Methodology Explanation
The NADAC was calculated using information from the most recently completed pharmacy survey.
The NADAC was calculated based on package size.
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Historical Pricing Trends & Acquisition Cost Benchmarks

Since Sep 2020, the NADAC wholesale price for (NDC ) has moved within a range of $3.77441 to $6.33374 per ML. Over this 5 years and 11 months period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.

Price Range
$3.7744 - $6.3337
Market Volatility
67.81% Variance
Latest Trend
0.40%

Recent NADAC Price History

DateUnit PriceUnitSourceMethodRate
Aug 19, 2026 $3.78944 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Jul 22, 2026 $3.77441 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Jun 17, 2026 $3.82686 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
May 20, 2026 $3.93605 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Apr 22, 2026 $4.01090 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Mar 18, 2026 $4.03566 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Feb 18, 2026 $4.02936 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Jan 21, 2026 $4.03920 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Dec 17, 2025 $4.08640 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Nov 19, 2025 $4.16355 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Oct 22, 2025 $4.32688 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic
Sep 17, 2025 $4.47176 MLC/I - Chain or Independent PharmacyCode 1, 5, 6G - Generic

Earlier NADAC Price History

Pricing Methodology Legend

  • Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
  • Code 5: The NADAC was calculated based on package size.
  • Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Understanding NADAC Pricing Data

The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.

Important Price Distinction:

The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.

NADAC Pricing Data Last Updated on: September 09, 2026